Quarterly report pursuant to Section 13 or 15(d)

Severance Charges

Severance Charges
6 Months Ended
Jun. 30, 2018
Restructuring And Related Activities [Abstract]  
Severance Charges



As a requirement for the closing of the Arrangement, OncoGenex terminated the employment of one senior executive. Severance payable at the date of the transaction was $1.2 million and has been accounted for in accordance with EITF No. 95-3 , “Recognition of Liabilities in Connection with a Purchase Business Combination” as part of the purchase price allocation (Note 4—Intangibles). The severance payable was settled following the completion of the Arrangement and no amounts were owing as at June 30, 2018.